tbuckley/cabot-search huggingface dataset:
Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8<sup>+</sup>CD28<sup>+ </sup>T Lymphocyte Responses
Authors: Jian He, Siliang Duan, Xia Yu, Zhiyong Qian, Sufang Zhou, Zhiyong Zhang, Xianing Huang, Yong Huang, Jing Su, Chunhui Lai, Jinyu Meng, Nuo Zhou, Xiaoling Lu, Yongxiang Zhao
Journal: Theranostics (2016)

Background: Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) has great potential for the treatment of some malignant cancers.Therefore, augmenting the responses of tumor-specific CTLs is significant for the adoptive immunotherapy of melanoma.This study aimed to investigate the anti-tumor response of a combination therapy employing folate-modified chitosan nanoparticles containing IP-10 (interferon-γ-inducible protein-10) plus melanoma TRP2-specific CD8 + CD28 + T cells.Methods: We prepared folate-modified chitosan nanoparticles containing the mouse IP-10 gene (FA-CS-mIP-10), and induced melanoma TRP2-specific CD8 + CD28 + T cells by co-culturing them with artificial antigen-presenting cells.B16-bearing mice were treated with FA-CS-mIP-10, melanoma TRP2-specific CD8 + CD28 + T cells, a combination of both, and the saline control.Tumor volumes and the survival time of mice were recorded.The proportion of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor microenvironment and regulatory T cells (Tregs) in the spleen was analyzed by flow cytometry.We also detected the proliferation and angiogenesis of tumors by immunohistochemistry and apoptosis by TUNEL. Results:The combination therapy inhibited the progression of melanoma in vivo.Compared with other treatments, it more efficiently inhibited tumor growth and increased the survival time of mice.After treatment with combination therapy, the proportion of MDSCs and Tregs decreased, while the percentage of CXCR3 + CD8 + T cells increased.Furthermore, combination therapy inhibited proliferation and promoted apoptosis of tumor cells and significantly inhibited tumor angiogenesis in vivo.Conclusion: We describe a novel strategy for improving the anti-tumor response of CD8 + CD28 + CTLs by combining them with FA-CS-mIP-10 nanoparticles.
Duodenal Carcinoembryonic Antigen in Patients With Benign and Malignant Diseases: Preliminary Observations23
Authors: Matthew S. Loewenstein, Prakash Rau, Robin A. Rittgers, Ballapuram G. Adhinarayanan, Herbert Z. Kupchik, Norman Zamcheck
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Duodenal Carcinoembryonic Antigen in Patients With Benign and Malignant Diseases: Preliminary Observations Get access Matthew S. Loewenstein, Matthew S. Loewenstein 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. 5Department of Medicine, Harvard Medical School, Boston, Mass. 02118. Search for other works by this author on: Oxford Academic PubMed Google Scholar Prakash Rau, Prakash Rau 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robin A. Rittgers, Robin A. Rittgers 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. Search for other works by this author on: Oxford Academic PubMed Google Scholar Ballapuram G. Adhinarayanan, Ballapuram G. Adhinarayanan 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. Search for other works by this author on: Oxford Academic PubMed Google Scholar Herbert Z. Kupchik, Herbert Z. Kupchik 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. Search for other works by this author on: Oxford Academic PubMed Google Scholar Norman Zamcheck Norman Zamcheck 4Mallory Gastrointestinal Research Laboratory, Boston City Hospital, Boston, Mass. 02118. 5Department of Medicine, Harvard Medical School, Boston, Mass. 02118. 6Department of Pathology, Boston University School of Medicine, Boston, Mass. 02118. 7We thank Mrs. Mary Edwards for her help in collecting the specimens and Mr. Michael DePasquale and Mr. Charles Kerea-koglow for their expert technical assistance. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 64, Issue 2, February 1980, Pages 235–240, https://doi.org/10.1093/jnci/64.2.235 Published: 01 February 1980 Article history Received: 04 April 1979 Accepted: 23 July 1979 Published: 01 February 1980
Transferrin Receptor Expression in Testis Cancer
Authors: D. P. PETRYLAK, A. YAGODA, K. M. O'TOOLE, A. CHADBURN, I. S. SAWCZUK, M. C. BENSON, C. A. OLSSON, L. ALLEGRETTA, A. D. SAAD, D. D. WARTINGER
Journal: JNCI Journal of the National Cancer Institute (1994)
Abstract 1593: Sulforaphane protects melanocytes and skin from individuals at increased risk for melanoma from the effects of UV radiation: Role of thioredoxin reductase 1.
Authors: Pamela B. Cassidy, John Quackenbush, Jennifer Campbell, Philip J. Moos, Sancy A. Leachman
Journal: Cancer Research (2012)

Abstract Our interest in the natural product sulforaphane (SF) began with studies of patients at high risk for melanoma. Germline loss-of-function (LOF) mutations in the highly polymorphic melanocortin-1 receptor gene (MC1R), confers a 4-fold increased risk for melanoma. Much of this increase arises from the loss of MC1R-mediated upregulation of antioxidant, pigment synthesis, DNA repair and anti-apoptotic pathways that protect epidermal melanocytes from the mutagenic effects of UV radiation. We have found that SF (likely due to its antioxidant activity) protects both normal human melanocytes, and the skin of human subjects with LOF MC1R mutations, from the harmful effects of UV light. Shave biopsies were harvested from donors with either wild-type MC1R or two LOF alleles. The epidermal tissues were treated ex vivo with UV and/or SF then analyzed histologically and by qPCR. Our results showed that SF provides significant protection from UV to both melanocytes and skin. We found also that the antioxidant protein thioredoxin reductase 1 (TR1) was significantly induced by SF. In order to explore the role of TR1 in protecting melanocytes from UV-induced damage, we have created a human melanocyte cell line that expresses a micro RNA which targets TR1. These cells display increased sensitivity to the effects of UV and differential processing of the pigment synthesis protein tyrosinase. This study demonstrates the promise of SF as an agent for protection of human skin in individuals with high-risk MC1R genotypes from the effects of UV light, and highlights the role of TR1 in this process. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1593. doi:1538-7445.AM2012-1593
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia
Authors: Alastair J.J. Wood, Alan Saven, Lawrence Piro
Journal: New England Journal of Medicine (1994)

Hairy-cell Leukemia, or leukemic reticuloendotheliosis, is an uncommon chronic lymphoproliferative disorder first described by Bouroncle et al. in 19581. Its defining features are mononuclear cells with prominent cytoplasmic projections (Figure 1) that retain acid phosphatase stain when treated with tartrate, and a typical pattern of cellular infiltration in the bone marrow and spleen1,2. In the marrow the hairy cells contain abundant pale cytoplasm, giving rise to a "fried egg" appearance, and in the spleen the disruption of normal sinus architecture results in the formation of blood-filled spaces. Immunophenotypic analysis of the circulating hairy cells reveals them to . . .
New Technique May Predict Relapse In Breast Cancer
Authors: K. Ruddon
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article New Technique May Predict Relapse In Breast Cancer Get access Kate Ruddon Kate Ruddon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 12, 17 August 1988, Pages 892–893, https://doi.org/10.1093/jnci/80.12.892 Published: 17 August 1988
A SIMPLE RISK SCORE TO REDUCE DOWNSTREAM CARDIOVASCULAR TESTING IN THE EMERGENCY DEPARTMENT AFTER SERIAL NEGATIVE TROPONINS: VALIDATION USING THE ROMICAT II COHORT
Authors: Paul Cremer, Amgad Mentias, Serge Harb, Shaden Khalaf, Ellen Mayer Sabik, Venu Menon, Wael Jaber
Journal: Journal of the American College of Cardiology (2016)
Abstract 1594: Chemopreventive action of <i>Piper nigrum</i> on cell proliferation and apoptosis in skin papillomagenesis and its influence on the levels/activity of enzymes associated with xenobiotic metabolism and antioxidant status in Swiss albino mice
Authors: Manju Singh
Journal: Cancer Research (2012)

Abstract Piper nigrum a spice, has widely used in various systems of traditional medicine. Therefore, the present study was designed to investigate the chemopreventive potential of P. nigrum on cell proliferation, apoptosis in DMBA-induced skin papillomagenesis and its influence on the levels/activity of enzymes associated with xenobiotic metabolism and antioxidant status in mice. Two different doses (2 and 4%) of P. nigrum were given orally to the mice in the test diet at peri-initiational stage. DMBA and croton oil was used to induce and promote skin papillomagenesis respectively. For biochemical studies, mice were given with the same doses of P. nigrum in the test diet for two weeks. There was a significant reduction in (i) tumor burden to 3.0 and 2.4 (positive control: 6.4); (ii) tumor volume to 1.7 and 2.4 (positive control: 4.7); and (iii) tumor incidence 60 % and 50 %, respectively in case of 2 and 4% test diet treated animals relative control (100%). P. nigrum treatment resulted in upregulation of Bax with concomitant decrease in antiapoptotic protein Bcl-2 and PCNA in mouse skin tumors. P. nigrum showed a significant increase in the content/activities of phase I and phase II enzymes with the test diets. A significant enhancement in the activities of antioxidant enzymes were observed at 2 and 4% test diets of P. nigrum. Glyoxalase I activity and the content of reduced glutathione were significantly elevated. Expectedly, the activity of lactate dehydrogenase, exhibited a significant reduction at both the doses of test diets. The Chemopreventive effect of P. nigrum could be credited to its ability to inhibit cell proliferation and enhance apoptosis as well as to modulate phase I, phase II enzyme systems and also antioxidant status. The present findings may have some significance from the point of view of lowering the risk of cancer in human population. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1594. doi:1538-7445.AM2012-1594
Factors influencing false negative diagnosis of 3D-MRI in pre-operative breast cancer patients.
Authors: K Hisamatsu, W Takiyama, N Hirabayashi, M Kaneko, T Ono, R Sakabe, Y Stou, S Saeki, H Mukaida, Y Yamashita
Journal: Cancer Research (2009)

Abstract Abstract #4005 Introduction: We presented 3D-MRI will be the useful breast imaging tool in diagnosing intraductal spread and tumor size in breast cancer patients (ASCO 2008). But, false negative cases were very important in breast conserving surgery and careful management was needed in 3D-MRI guided surgery. This study was to review imaging diagnosis using 3D-MRI and to evaluate factors influencing false negative diagnosis of 3D-MRI, retrospectively. Material and methods: From July 2000, pre-operative 3D-MRI was underwent 433 cases of breast cancer patients. Images were obtained 426 cases (98%). Tumor size between 3D-MRI and resected specimens were evaluated retrospectively. Cases with tumor size difference between 3D-MRI and resected specimens less than 1cm were defined related cases and cases with tumor size in 3D-MRI was 1cm more smaller than resected specimens were defined false negative cases. Investigated factors influencing false negative diagnosis of 3D-MRI were age, patterns of 3D-MRI images, presence of pre-operative chemotherapy, histological type, histological grade, microscopical invasive tumor size (mm) and presence of ductal spreading. From April 2005, the entire specimen was serially step cut and evaluated. Results: Tumor diameter from nipple side to lateral margin were measured by MRI and specimens, tumor size was correlated between MRI and specimens, significantly (n=118, r=07186, P &amp;lt; 0.001). On Multivariate analysis revealed that factors influencing 3D-MRI diagnosis were presence of ductal spreading (p=0.0002), patterns of 3D-MRI images (p=0.06) and presence of pre-operative chemotherapy (P=0.04). Factors influencing false negative diagnosis of 3D-MRI were presence of pre-operative chemotherapy (P&amp;lt;0.05), presence of ductal spreading (P&amp;lt;0.01) and infiltration of lymphocyte in the edge of ductal spreading (P&amp;lt;0.05). Selection for breast conserving surgery and margin width were based by 3D-MRI images. The proportion of breast-conserved surgery were obtained 89% (380/426 cases) and local failure seen only 6 cases (local failure rate 1.4%) in 3D-MRI guided surgery. (6-94 months, median follow up 51 months).&amp;#x2028; Conclusion: These results suggest that MRI will be the useful breast imaging tool in diagnosing intraductal spread and tumor size in breast cancer patients. But, caution will be needed in cases with pre-operative systemic therapy and cases expected ductal spreading by other imaging tools. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4005.
Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors
Authors: Judith Michels, Ilio Vitale, Lorenzo Galluzzi, Oliver Kepp, Laura Senovilla, Ken André Olaussen, Jean-Charles Soria, Maria Castedo, Guido Kroemer
Journal: Cancer Research (2012)

Abstract Chemical inhibitors of poly(ADP)ribose (PAR) polymerases (PARP) have generated raising expectations in cancer treatment, either as monotherapeutic agents for the therapy of tumors that are deficient in DNA repair by homologous recombination, or combined with DNA-damaging compounds. Results from early clinical trials suggest that PARP inhibitors are well tolerated, and would be particularly useful for BRCA1- and BRCA2-mutated tumors. However, as these tumors constitute a minor fraction of all cancers, the main challenge is to extend the efficacy of PARP inhibitors to BRCA-proficient tumors, calling for the need of reliable biomarkers that predict the efficiency of PARP inhibitor-based therapy. Here, we report the effects of two chemically distinct PARP inhibitors, the phenanthridinone PJ34 and the 4-methoxy-carbazole derivate CEP8983, on non-small cell lung cancer (NSCLC) cells exhibiting increased PARP activity. We found that PAR polymers are a predictive marker of the sensitivity of NSCLC cells to PARP inhibitors. We were able to confirm these findings in mesothelioma, cervical cancer and ovarian cancer cell lines that are characterized by constitutively increased expression of PARP (as monitored by immunoblotting with a PARP1-specific antibody) as well as enhanced PARP enzymatic activity (as detected by immunoblotting with an antibody that recognizes poly(ADP)ribosylated proteins). Upon treatment with PARP inhibitors, cells with hyperactivated PARP exhibited signs of DNA damage (as assessed by immunofluorescence microscopy with an antibody that recognizes the phosphorylated form of histone 2AX) and underwent cell death via the intrinsic pathway of apoptosis (as monitored by immunofluorescence microscopy with antibodies for the detection of cytochrome c and active caspase-3). The chemosensitizing or cell death-inducing effects of PJ34 and CEP8983 were mimicked by PARP1- and PARP2-specific siRNAs, suggesting that they are indeed mediated by PARP inhibition. Moreover, PARP inhibitors efficiently reduced the growth of NSCLC xenografts exhibiting increased PARP activity (as evaluated by immunohistochemistry for poly(ADP)ribosylated proteins on paraffin embedded xenografts). Altogether, our results indicate that PARP overactivation reflects the susceptibility of NSCLC cells to apoptosis induction by PARP inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3115. doi:1538-7445.AM2012-3115
DOPPLER INDICES OF RESISTANCE ARE SUPERIOR TO THERMODILUTION INDICES AT PREDICTING CORONARY MICROVASCULAR DYSFUNCTION
Authors: Rupert Williams, Kalpa De Silva, Matthew Lumley, Kaleab Asrress, Satpal Arri, Howard Ellis, Awais Mir, Brian Clapp, Michael Marber, Amedeo Chiribiri, Sven Plein, Simon Redwood, Divaka Perera
Journal: Journal of the American College of Cardiology (2015)
Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow Cytometry
Authors: Gary M. Clark, Lynn G. Dressler, Marilyn A. Owens, George Pounds, Teri Oldaker, William L. McGuire
Journal: New England Journal of Medicine (1989)

More accurate prediction of the prognosis in women with node-negative breast cancer may improve physicians' ability to identify the patients most likely to benefit from systematic adjuvant therapy. With this in mind, we performed DNA flow-cytometric measurements of ploidy and the fraction of cells in the synthesis phase of the cell cycle (S-phase fraction) on 395 specimens of node-negative breast cancer from our bank of frozen tumors, using the aliquots of pulverized frozen tissue from steroid-receptor assays. The median duration of follow-up in patients still alive at the time of analysis was 59 months. Thirty-two percent of the 345 specimens that could be evaluated were diploid, and 68 percent were aneuploid. The probability of disease-free survival at five years was 88±3 percent in patients with diploid tumors and 74±3 percent in those with aneuploid tumors (P = 0.02). The S-phase fraction was not a significant additional predictor of disease-free survival in patients with aneuploid tumors. However, the probability of disease-free survival in patients with diploid tumors and low S-phase fractions was 90±3 percent at five years, as compared with 70±13 percent in those with diploid tumors and high S-phase fractions (P = 0.007). Similar differences in overall survival were noted. We conclude that DNA flow-cytometric measurements of ploidy and S-phase fraction can be performed on frozen specimens of tumors and are potentially important predictors of disease-free and overall survival in patients with node-negative breast cancer. (N Engl J Med 1989; 320:627–33.)
Antitumor activity of chemoendocrine therapy in premenopausal (capecitabine [CAP] + tamoxifen [TAM]) and postmenopausal (CAP + letrozole [LET]) human breast cancer [BC] xenograft models.
Authors: M Kataoka, Y Yamaguchi, N Sawada, Y Moriya, DB Evans, H Yasuno, K Mori, S Hayashi
Journal: Cancer Research (2009)

Abstract Abstract #2012 Background: The preferential treatment for estrogen receptor (ER)-positive metastatic or recurrent breast cancer is endocrine therapy unless it is life-threatening. CAP, an oral fluoropyrimidine, is activated to 5-FU by thymidine phosphorylase (TP) in tumors. We have evaluated the efficacy of endocrine therapy in combination with CAP in premenopausal and postmenopausal ER-positive human BC xenograft models.&amp;#x2028; Methods: In a premenopausal BC model, ER-positive MCF7 cells were subcutaneously (sc) inoculated into nude mice which had been implanted sc with 0.25 mg 17β-estradiol pellets. The mice received 6 weeks oral therapy with vehicle, CAP (days 1-14, every 3 weeks) at the maximal tolerated dose (MTD) of 539 mg/kg or 2/3 MTD +/- TAM at 100 or 30 mg/kg/day. In a postmenopausal BC model, nude mice were ovariectomized and implanted sc with 1.5 mg androstenedione pellets the day before tumor cell inoculation. MCF7A25F3 cells, an aromatase gene transfectant of MCF7, were inoculated sc into the mice. The mice received 6 weeks' oral administration of vehicle, CAP (days 1-14, every 3 weeks) at 2/3 MTD +/- LET at 0.1 mg/kg/day. TP level in tumors was measured on the final day of the first treatment cycle by ELISA. In vitro ER reporter gene assays were performed by co-culturing MCF7 cells transfected with estrogen response element-GFP gene with stromal cells isolated from human BC tissues. Testosterone was added to the culture medium as a substrate for aromatase and the expression of GFP was measured.&amp;#x2028; Results: In the premenopausal model, the antitumor activity of the combination therapy with CAP and TAM was significantly superior to that of each monotherapy (p&amp;lt;0.001). In the postmenopausal model, the antitumor activity of the combination therapy with CAP and LET was also significantly superior to that of each monotherapy (p&amp;lt;0.05). No augmentation of toxicity in terms of body weight loss was observed with the combination therapy in each xenograft model. In the premenopausal model, the tumor levels of TP were up-regulated (p&amp;lt;0.05) by TAM treatment indicating that TAM might potentiate the antitumor activity of CAP. On the other hand, the tumor levels of TP remained unchanged by LET treatment in the postmenopausal model. In ER reporter gene assays, GFP expression was decreased by the addition of either 5'-deoxy-5-fluorouridine (5'-DFUR, an intermediate of CAP), 4-hydroxytamoxifen (4-OHT, active form of TAM) or LET in a concentration-dependent manner. 5'-DFUR showed at least additive inhibitory effect in combination with 4-OHT or LET.&amp;#x2028; Conclusion: Chemoendocrine therapy using CAP might be a useful treatment modality for BC patients regardless of the menopausal status. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2012.
Role of Low Dose Capecitabine in Inoperable Cancer Gallbladder in Presence of Jaundice: a Pilot Study From Endemic World
Authors: Abhinav Sonkar, Jitendra Kushwaha, Manoj Kumar, Abhijit Chandra, Ravi Gupta, Devendra Singh, Awanish Kumar, Akshay Agarwal
Journal: Annals of Oncology (2013)